Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Trastuzumab Deruxtecan + Nivolumab in HER2+ Esophageal/GEJ Cancer
NCT05480384Phase 2Active, not recruiting
- Sponsor
- Brown University
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, nivolumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Brown University. Started Jul 2023; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecannivolumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05480384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480384.